Table 1.

Patient characteristics

	Total		AML-BFM 2004		AML-BFM 98		AML-BFM 93
	n	%	n	%	n	%	n	%	p-value
Registered patients	249		99		82		68
Protocol patients	193	78	94	95	57	70	42	63	< 0.0001
Age
Median (Q1–Q3)	9.5	(2.5–13.4)	8.6	(2.2–14.6)	9.9	(3.0–12.8)	9.5	(2.9–12.2)	0.675
< 1 year	15	8	7	7	3	5	5	12	0.862
1≤ 10 years	88	45	45	48	27	47	16	37
≥ 10 years	91	47	42	45	27	47	22	51
Gender
Males	96	50	46	49	27	47	23	55	0.605
Females	97	50	48	51	30	53	19	45
Leukocytes (× 109/l)
< 10	93	48	47	50	27	47	19	45	0.552
10–< 100	71	37	36	38	17	30	18	43
≥ 100	29	15	11	12	13	23	5	12
CNS leukemia	11	6	8	7	2	4	1	2	0.129
FAB types
M0	12	6	5	5	3	5	4	10	0.508
M1	19	10	11	12	7	12	1	2
M2	53	27	27	29	13	23	13	31
M3	21	11	12	13	5	9	4	10
M4	24	12	5	5	10	18	9	21
M4Eo	18	9	8	9	8	14	2	5
M5	24	12	13	14	5	9	6	14
M6	1	1	1	1	0	0	0	0
M7	19	10	10	11	6	11	3	7
Other	1	1	1	1	0	0	0	0
Not classified	1	1	1	1	0	0	0	0
Genetic aberrations
t(8;21)	20	10	9	10	5	9	6	14	0.606
t(15;17)	19	10	10	11	5	9	4	10
inv(16)	18	9	7	7	8	14	3	7
MLL	45	23	19	20	13	23	13	30
Normal	26	13	12	13	9	16	5	12
Other	52	27	29	30	13	23	10	23
Down	11	6	7	7	4	7	n.a.	n.a.
Not classified	2	1	1	1	0	0	1	2
Risk group
SR	72	37	36	38	22	39	14	33	0.735
HR	117	61	58	62	32	56	27	64
Not classified	4	2	0	0	3	5	1	2
Median follow-up
In years (Q1–Q3)	6.7	(4.0–9.7)	4.0	(1.8–6.0)	9.0	(7.9–10.5)	11.6	(9.0–15.0)

AML acute myeloid leukemia, CNS central nervous system, SR standard risk, HR high-risk